Parkinson’s affects over 10 million individuals worldwide, but there is currently no cure and only limited treatments to manage its progression, which impacts both motor and nonmotor functions. This wide range of manifestations makes it difficult to both fully capture the real-life experiences of individuals living with Parkinson’s and to measure the efficacy of drugs in clinical trials in this heterogeneous population.
Existing approaches and measures used to evaluate Parkinson’s fail to capture the aspects of the disease that hold genuine significance for people living with Parkinson’s and their care partners. Thus, there is an urgent need to redefine and expand our understanding of the early stages of Parkinson’s.
The focus on the impact of early-stage Parkinson’s will enable us to reach a greater number of individuals affected by the disease and effectively address their specific needs, ensuring improved outcomes and a better quality of life.
The goal of the CPP Consortium is to broadly advance the drug development landscape for Parkinson’s prevention and treatment by working collaboratively with the PD global community to share data, knowledge and resources towards the development and regulatory endorsement of novel drug development tools.
We do this by prioritizing efforts focused on broadening populations for trial recruitment, collecting, understanding and sharing real-world data, and by leveraging innovative technologies to capture what truly matters.
With a focus on the “right drug, right patient, right time” approach, CPP streamlines regulatory processes to optimize drug development with greater efficiency in advancing data-driven solutions for clinical trials. CPP aims to align with regulatory strategies spanning from model-informed drug development, patient-focused drug development, digital heath technologies, biomarkers, and real-world data.